Clinical trials: Pulmonary Embolism Acute Massive
Pulmonary Embolism
Multicenter, Nonrandomized, Prospective Study of Pulmonary Embolism Removal With the AngioJet 6F Ultra System
The purpose of this European Post Market Follow-up Plan is designed to evaluate the safety, efficacy, adverse events and any new information that may surface regarding the use of the AngioJet Ultra PE Thrombectomy Catheter System…
- Trial name
- PERFUSE (NCT01638468)
- Testing
- AngioJet Ultra PE Thrombectomy System
- Where
- 7 sites in Germany, Italy and 2 more
- Volunteers
- 7 people
- Sponsor
- Boston Scientific Corporation
Pulmonary Embolism, Pulmonary Embolus/Emboli
Non-Invasive Measurement of Cardiac Output and Stroke Volume in PE
Pulmonary embolism impacts over 1 in 1000 adults annually and is the third leading cause of cardiovascular death after heart attack and stroke. The consequence of each PE is widely variable.
- Conditions
- Pulmonary Embolism, Pulmonary Embolus/Emboli, Pulmonary Disease, Pulmonary Embolism and Thrombosis
- Trial name
- NCT04855370
- Testing
- Non-invasive hemodynamic measurements
- Where
- United States
- Sponsor
- University of California, Los Angeles
Pulmonary Embolism Acute, Pulmonary Embolism Acute Massive
Cohort Study on Treatment Comes of Catheter-based Therapy in Patients With Acute Pulmonary Embolism in Hong Kong
This retrospective cohort study (Hong Kong PECT Registry) compares treatment outcomes between different percutaneous catheter-based therapies in patients with acute pulmonary embolism (PE).
- Conditions
- Pulmonary Embolism Acute, Pulmonary Embolism Acute Massive, Pulmonary Embolism Subacute Massive
- Trial name
- HK-PECT (NCT07029841)
- Testing
- catheter-based therapy
- Where
- Hong Kong
- Volunteers
- 1,000 people
- Sponsor
- Chinese University of Hong Kong
PE - Pulmonary Embolism, PE - Pulmonary Thromboembolism
FlowTriever for Acute Massive Pulmonary Embolism (FLAME)
To evaluate treatment outcomes of patients diagnosed with high-risk (massive) pulmonary embolism
- Trial name
- FLAME (NCT04795167)
- Where
- 11 sites in United States
- Volunteers
- 115 people
- Sponsor
- Inari Medical
Pulmonary Embolism, Pulmonary Embolism Acute Massive
Registry of Catheter Intervention in Pulmonary Embolism
Multicenter longitudinal observational ambispective (retrospective cases from 2014 and prospective from 2018 onwards) cohort study.
- Conditions
- Pulmonary Embolism, Pulmonary Embolism Acute Massive, Pulmonary Embolism Acute, Pulmonary Embolism and Thrombosis
- Trial name
- RiTEP (NCT06348459)
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Hospital San Carlos, Madrid
PE - Pulmonary Embolism, PE - Pulmonary Thromboembolism
Stent-Retriever for Acute Massive Pulmonary Embolism (SRAME)
To evaluate treatment outcomes of patients diagnosed with pulmonary embolism.
- Trial name
- SRAME (NCT05992168)
- Testing
- Stent-Retriever
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Suzhou Zenith Vascular SciTech Limited
Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism
Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
The purpose of this study is to examine the degree to which pulmonary embolism (clot) can be dissolved when treated with a very low dose of a systemic thrombolytic drug (clot buster) along with standard anticoagulant therapy as…
- Conditions
- Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism, Pulmonary Embolism With Pulmonary Infarction, Pulmonary Embolism Subacute Massive
- Trial name
- SAFE-LYSE (NCT03988842)
- Testing
- Alteplase, Unfractionated heparin, Apixaban
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Victor Tapson, MD
Trauma
Pragmatic, Randomized Optimal Platelet and Plasma Ratios
Pragmatic, Randomized, Optimal Platelet and Plasma Ratios (PROPPR)is a Phase III trial designed to evaluate the difference in 24-hour and 30-day mortality among subjects predicted to receive massive transfusion ([MT] (defined as…
- Trial name
- PROPPR (NCT01545232)
- Testing
- 1:1:1 Blood Transfusion Ratio, 1:1:2 Blood Transfusion Ratio
- Where
- 12 sites in United States, Canada
- Volunteers
- 680 people
- Sponsor
- The University of Texas Health Science Center, Houston
Angiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy
Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy
A prospective randomised controlled study to evaluate outcomes of the treatment with pradaxa or warfarin for prevention of recurrent DVT in patients with angiographically confirmed acute massive pulmonary embolism undergoIng…
- Trial name
- Re-Spire (NCT02979561)
- Testing
- Dabigatran Etexilate, Warfarin
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Pulmonary Embolism Acute Massive
Early Catheter-directed Treatment of High Risk Pulmonary Embolism
Prospective, multicenter, open label, randomized controlled clinical trial to compare the effects of an early catheter-directed treatment plus conventional care with conventional care in patients with high-risk pulmonary embolism
- Trial name
- CATCH-PE II (NCT06672081)
- Testing
- Early Catheter-Interventional Treatment, Conventional care
- Where
- 18 sites in Germany
- Volunteers
- 210 people
- Sponsor
- Leipzig Heart Science gGmbH
Pulmonary Embolism
DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)
The primary objective of this study is to evaluate safety and initial effectiveness of DS-9231 when taken together with current standard of care.
- Trial name
- NCT03316729
- Testing
- DS-9231
- Sponsor
- Daiichi Sankyo
Pulmonary Embolism, Acute Pulmonary Embolism
Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
The purpose of this study is to determine if the EKOS EkoSonic® Endovascular Device when used in conjunction with recombinant tissue plasminogen activator (t-PA) as a treatment for acute PE will decrease the ratio of right…
- Conditions
- Pulmonary Embolism, Acute Pulmonary Embolism, Sub-massive Pulmonary Embolism, Massive Pulmonary Embolism
- Trial name
- SEATTLE II (NCT01513759)
- Testing
- recombinant tissue plasminogen activator, EKOS EkoSonic Endovascular System
- Where
- 22 sites in United States
- Volunteers
- 150 people
- Sponsor
- Boston Scientific Corporation
Pulmonary Embolism Acute Massive
Post-registration Trial of the Non-immunogenic Staphylokinase in Massive Pulmonary Embolism
The aim of FORPE Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with massive pulmonary embolism in routine clinical practice.
- Trial name
- NCT07245927
- Testing
- Non-immunogenic staphylokinasenon-immunogenic staphylokinase 15 mg as a single intravenous bolus Other Names: Fortelyzin®
- Where
- 14 sites in Russia
- Volunteers
- 20,000 people
- Sponsor
- Supergene, LLC
Pulmonary Embolism
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial
Phase II trial of TS23
- Trial name
- NAIL-IT (NCT05408546)
- Testing
- TS23
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Translational Sciences, Inc.
Pulmonary Embolism, Acute Pulmonary Embolism
FlowTriever Pulmonary Embolectomy Clinical Study
Evaluate the safety and effectiveness of the FlowTriever System for use in the removal of emboli from the pulmonary arteries in the treatment of acute pulmonary embolism.
- Conditions
- Pulmonary Embolism, Acute Pulmonary Embolism, Submassive Pulmonary Embolism, Massive Pulmonary Embolism
- Trial name
- FLARE (NCT02692586)
- Testing
- FlowTriever System
- Where
- 18 sites in United States
- Volunteers
- 106 people
- Sponsor
- Inari Medical
Heart Failure, Cardiomyopathies
Multimodal Physiologic State Intelligence Study
The OMNIPHYS study will investigate whether multimodal ultrasound and other routinely collected clinical and physiologic data can be combined with artificial intelligence to characterize changes in a person's physiologic state…
- Conditions
- Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute
- Trial name
- OMNIPHYS (NCT07814118)
- Testing
- OMNIPHYS Multimodal Ultrasound Imaging System
- Where
- United States
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.